Toujeo Market Report 2026

Toujeo Market Overview

• The Toujeo market growth in the historic period has been driven by rising prevalence of type 1 and type 2 diabetes, increased clinical acceptance of insulin glargine • Market expansion is supported by increasing diabetes incidence globally, growing demand for convenient insulin administration • Growth Driver: Rising Prevalence Of Diabetes Driving Market Growth Due To Increasing Insulin Therapy Demand • North America was the largest region in 2025.

What Is Covered Under Toujeo Market?

Toujeo is a long-acting insulin that contains insulin glargine, used to help control blood sugar levels in people with diabetes. It contains insulin glargine, a synthetic form that helps regulate blood glucose by providing a steady insulin release over an extended period, typically up to 24 hours. The main types of indications of toujeo are type 1 diabetes, type 2 diabetes, and pediatric diabetes. Type 1 diabetes is an autoimmune condition where the body’s immune system attacks insulin-producing cells in the pancreas, leading to little or no insulin production. It is formulated through prefilled pens and vials, distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. And cater to various end users such as adult, geriatric, and pediatric.

What Is The Toujeo Market Growth Forecast?

The growth in the forecast period can be attributed to increasing diabetes incidence globally, growing demand for convenient insulin administration, rising focus on long-term glycemic control, expansion of access to specialty diabetes care, increasing adoption of advanced insulin delivery formats. Major trends in the forecast period include increasing adoption of long-acting basal insulin therapies, growing preference for once-daily insulin regimens, rising use of prefilled insulin delivery devices, expansion of patient-centric diabetes management approaches, enhanced focus on glycemic stability.

Global Toujeo Market Segmentation

1) By Indication: Type 1 Diabetes, Type 2 Diabetes, Pediatric Diabetes 2) By Formulation: Prefilled Pens, Vials 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 4) By End User: Adult, Geriatric, Pediatric

What Are The Drivers Of The Toujeo Market?

The rising prevalence of diabetes is expected to propel the growth of the toujeo market going forward. Diabetes is a chronic medical condition where the body cannot properly regulate blood sugar (glucose) levels due to insufficient insulin production or inability to use insulin effectively. The prevalence of diabetes is attributed to factors such as unhealthy diets and sedentary lifestyles, both of which contribute significantly to the increasing incidence of the condition worldwide. Toujeo manages blood sugar levels in people with type 1 and type 2 diabetes by providing a steady release of insulin over 24 hours, typically through a once-daily injection. For instance, in 2025, according to the International Diabetes Federation, a Belgium-based health organization, in 2024, around 589 million adults aged 20-79 were living with diabetes, with the total number projected to reach 853 million by 2050 and with more than 4 in 5 adults with diabetes residing in low and middle income countries. Therefore, the rising prevalence of diabetes is driving the growth of the toujeo industry. The rising demand for personalized medicine is expected to propel the growth of the toujeo market going forward. Personalized medicine refers to a medical approach that tailors the prevention, diagnosis, and treatment of diseases to an individual’s unique genetic, environmental, and lifestyle factors. Rising demand for personalized medicine is primarily driven by the increasing prevalence of chronic and genetic diseases, which necessitates tailored treatments that improve patient outcomes and reduce adverse effects. Personalized medicine supports Toujeo by enabling tailored insulin therapies that match individual patients’ genetic profiles, lifestyles, and glycemic patterns, thereby improving efficacy and minimizing adverse effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine drives the toujeo industry. The rising healthcare investments are expected to propel the growth of the toujeo market going forward. Healthcare investments refer to allocating capital into the healthcare sector, including funding for medical technologies, pharmaceuticals, healthcare facilities, and services. The rise in healthcare investments is due to the aging population, which increases demand for healthcare services, and advancements in medical technology drive innovation and improve patient care. Healthcare investments are used for toujeo to fund clinical trials, expand production, secure regulatory approvals, and enhance distribution to ensure wider accessibility and adoption of the treatment. For instance, in December 2024, according to Health Affairs, a US-basedhealth policy journal, health care spending in the United States reached $4.9 trillion and increased by 7.5 percent in 2023, up from a growth rate of 4.6 percent in 2022. Therefore, rising healthcare investments are driving the growth of the toujeo industry.

Key Players In The Global Toujeo Market

Major companies operating in the toujeo market are Sanofi SA

Regional Insights

North America was the largest region in the toujeo market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Toujeo Market?

The toujeo market consists of sales of prefilled insulin pens, insulin detemir, insulin aspart, and insulin glargine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Toujeo Market Report 2026?

The toujeo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the toujeo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.